Survival of patients with pacing-induced cardiomyopathy upgraded to CRT does not depend on defibrillation therapy

Pacing Clin Electrophysiol. 2020 May;43(5):471-478. doi: 10.1111/pace.13906. Epub 2020 Apr 15.

Abstract

Background: Permanent right ventricular pacing (RVP) results in cardiac dyssynchrony that may lead to heart failure and may be an indication for the use of cardiac resynchronization therapy (CRT). The study aimed to evaluate predictors of outcomes in patients with pacing-induced cardiomyopathy (PICM) if upgraded to CRT.

Methods: One hundred fifteen patients, 75.0 years old (IQR 67.0-80.0), were upgraded to CRT due to the decline in left ventricle ejection fraction (LVEF) caused by the long-term RVP. A retrospective analysis was performed using data from hospital and outpatient clinic records and survival data from the National Health System.

Results: The prior percentage of RVP was 100.0% (IQR 97.0-100.0), with a QRS duration of 180.0 ms (IQR 160.0-200.0). LVEF at the time of the upgrade procedure was 27.0% (IQR 21.0-32.75). The mean follow-up was 980 ± 522 days. The primary endpoint, death from any cause, was met by 26 (22%) patients. Age > 82 years (HR 5.96; 95% CI 2.24-15.89; P = .0004) and pre-CRT implantation LVEF < 20% (HR 5.63; 95%CI 2.19-14.47; P = .0003), but neither the cardioverter-defibrillator (ICD) implantation (HR 1.00; 95%CI 0.45-2.22; P = 1.00), nor the presence of atrial fibrillation (HR 1.22; 95%CI 0.56-2.64; P = .62), were independently associated with all-cause mortality.

Conclusion: Advanced age and an extremely low LVEF, but neither the presence of atrial fibrillation nor implanting an additional high voltage lead, influence the all-cause mortality in patients after long-term RVP, when upgraded to CRT.

Keywords: cardiac resynchronization therapy upgrade; chronic right ventricular pacing; defibrillator; pacing-induced cardiomyopathy.

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Cardiac Pacing, Artificial / adverse effects*
  • Cardiac Resynchronization Therapy / methods*
  • Cardiomyopathies / etiology*
  • Cardiomyopathies / mortality
  • Cardiomyopathies / physiopathology
  • Cardiomyopathies / therapy*
  • Female
  • Humans
  • Male
  • Retrospective Studies
  • Risk Factors
  • Secondary Prevention
  • Survival Rate
  • Ventricular Dysfunction, Left / etiology*
  • Ventricular Dysfunction, Left / mortality
  • Ventricular Dysfunction, Left / physiopathology
  • Ventricular Dysfunction, Left / therapy*